Biofrontera AG/ DE000A4BGGM7 /
| 8/30/2019 12:00:00 AM | Chg. - | Volume | Bid1:17:23 PM | Ask10:51:54 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 2.92EUR | - | 135 Turnover: - |
-Bid Size: - | -Ask Size: - | 8.37 mill.EUR | - | - |
GlobeNewswire
8/14
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
6/24
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
GlobeNewswire
11/10/2023
The Benchmark Company Announces Upcoming 12th Annual Discovery One-on-One Investor Conference
GlobeNewswire
10/9/2023
ROTH MKM to Host Healthcare Opportunities Conference on October 12th at the Yale Club in New York Ci...
GlobeNewswire
3/17/2022
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of De...
GlobeNewswire
3/14/2022
Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Prote...
GlobeNewswire
2/14/2022
Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
GlobeNewswire
2/1/2022
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBC...
GlobeNewswire
1/18/2022
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the S...
GlobeNewswire
1/13/2022
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
GlobeNewswire
1/10/2022
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
GlobeNewswire
12/30/2021
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant...
GlobeNewswire
12/13/2021
Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz®...
GlobeNewswire
12/8/2021
Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
GlobeNewswire
12/6/2021
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with ...
GlobeNewswire
12/2/2021
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
GlobeNewswire
11/30/2021
Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
GlobeNewswire
11/29/2021
Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
11/23/2021
Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021
GlobeNewswire
11/18/2021
The Benchmark Company Announces Its Upcoming 10th Annual One-on-One Discovery Conference
GlobeNewswire
11/17/2021
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
